Anti-inflammatory trends of 1, 3-Diphenyl-2-propen-1-one derivatives

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 87-94

  Bukhari, Syed Nasir Abbas ^a   Jantan, Ibrahim ^a   Jasamai, Malina ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Anti inflammatory; Chalcones; Cyclooxygenase (COX); Heme oxygenase1(HO 1); Interleukin 5 (IL 5); Lipid peroxidation; Nitric oxide (NO)

Indexed keywords

1, 3 DIPHENYL 2 PROPEN 1 ONE DERIVATIVE; CELL ADHESION MOLECULE; CHALCONE DERIVATIVE; HEME OXYGENASE 1; INTERLEUKIN 5; ISOLIQUIRITIGENIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; HUMAN; IC 50; LIPID PEROXIDATION; MACROPHAGE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

EID: 84874583665     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955713804484767     Document Type: Article

References (49)

1. Avila, H. et al. Structure-activity relationship of antibacterial chalcones. Bioorg. Med. Chem., 2008, 16, 9790-9794.
2. Nowakowska, Z. A review of anti-infective and anti-inflammatory chalcones. Eur. J. Med. Chem., 2007, 42, 125-137.
3. Rajendra, P.Y. et al. Synthesis of Some 4'-Amino Chalcones and their Antiinflammatory and Antimicrobial Activity. Asian J. Chem., 2009, 21, 907.
4. Lahtchev, K.L. et al. Antifungal activity of chalcones: A mechanistic study using various yeast strains. Eur. J. Med. Chem., 2008, 43, 2220-2228.
5. Dominguez, J. et al. Synthesis and Evaluation of New Antimalarial Phenylurenyl Chalcone Derivatives. J. Med. Chem., 2005, 48, 3654-3658.
6. Valla, A. et al. Newsyntheses and potential antimalarial activities of new retinoid-like chalcones. Eur. J. Med. Chem., 2006, 41, 142-146.
7. Seo, W. et al. Evaluationof anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur. J. Med. Chem., 2010, 45, 2010-2017.
8. Tomar, V. et al. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders Bioorg. Med. Chem., 2007, 17, 5321-5324.
9. Nowakowska, Z. et al. Synthesis, physicochemical properties and antimicrobial evaluation of new (E)-chalcones. Eur. J. Med. Chem., 2008, 43, 707-713.
10. Trivedi, J.C. et al. Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Lett., 2007, 48, 8472-8474.
11. Lin, Y.M. et al. Chalcones and flavonoids as anti-Tuberculosis agents Bioorg. Med. Chem., 2002, 10, 2795-2802.
12. Vogel S et al. Natural and non-natural prenylated chalcones: Synthesis, cytotoxicity and anti-oxidative activity. Bioorg. Med. Chem., 2008, 16, 4286-4293.
13. Gacche RN et al. Enz. Inhib. Med. Chem., 2008, 23, 28-31.
14. Ducki S et al. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem Lett.,1998, 8, 1051-1055.
15. Boeck P et al. Synthesis of chalcone analogues with increased antileishmanial activity. Bioorg. Med. Chem., 2006, 14, 1538-1545.
16. Zhao L et al. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 5027-5029.
17. Won SJ et al. Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. Eur. J. Med. Chem., 2005, 40, 103-112.
18. Ducki S. The development of chalcones as promising anticancer agents. Drugs, 2007, 10, 42-46.
19. Gacche, R. et al. Antioxidant and anti-inflammatory related activities of selected synthetic chalcones: Structure-activity relationship studies using computational tools. Chem. Pharm. Bull., 2008, 56, 897-901.
20. Hwang, T.L. et al. Inhibition of superoxide anion neurophils by 3'-isopropoxychalcone via a cAMP-dependent pathway. Br. J. Pharmacol., 2006, 148, 78-87.
21. Sawle, P. et al. Strucute-activity relationship of methoxychalcones as inducers of heme oxygenase-1. Chem. Res. Toxicol., 2008, 21, 1484-1894
22. Jin, F. et al. Structural requirements of 2',4',6'-tris(methoxymethoxy)chalcone derivatives for anti-inflammatory activity: The importance of a 2'-hydroxy moiety. Arch. Pharm. Res., 2007, 30, 1359-67.
23. Foresti, R. et al. Differential activation of heme oxygenase-1 by chalcones and rosolic acid in endothelial cells. J. Pharmacol. Exp. Ther., 2005, 312, 686-93.
24. Chiaradia, L.D. et al. Synthesis and pharmacological activity of chalcones derived from 2.4.6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: Quantitative structure-activity relationship. Bioorg. Med. Chem., 2008, 16, 658-67.
25. Yang, H.M. et al. Structural requirement of chalcones for the inhibitory activity of interleukin-5. Bioorg. Med. Chem., 2007, 15, 104-11.
26. Pandey, M.K. et al. Butein, a tetrahydroxychalcone, inhibits Nuclear Factor (NF)-kB and NF-kB-regulated gene expression through direct inhibition of IkB kinase γ on cysteine-179 residue. J. Biol. Chem., 2007, 282, 17340-50.
27. Folmer, F. et al. Inhibition of TNFα-induced activation of nuclear factor kB by kava (Piper methysticum) derivatives. Biochem. Pharmacol., 2006, 71, 1206-18.
28. Cho, Y.C. et al. Differential anti-inflammatory pathway by xanthohumol in IFN-γ and LPS-activated macrophages. Int. Immunopharmacol., 2008, 8, 567-73.
29. Kim, J.Y. et al. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kB in RAW 264.7 macrophages. Eur. J. Pharmacol., 2008, 584, 175-84.
30. Alcaraz, M.J. et al. Role of nuclear factor-kB and oxygenase-1 in the mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells. Br. J. Pharmacol., 2004, 142, 1191-9.
31. Ahmad, S. et al. Cardamonin, inhibits proinflammatory mediators in activated RAW 264.7 cells and whole blood. Eur. J. Pharmacol., 2006, 538, 188-94.
32. Israf, D.A. et al. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kB nuclear translocation and Ik-B phosphorylation in RAW 264.7 macrophage cells. Mol. Immunol., 2007, 44, 673-679.
33. Hatziieremia, S. et al. The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkB signaling pathways in monocytes/macrophages. Br. J. Pharmacol., 2006, 149, 188-98.
34. Hirai, S. et al. Inhibitory effect of naringenin chalcone on inflammatory changes in the interaction between adipocytes and macrophages. Life Sci., 2007, 81, 1272-9.
35. STATENS SERUM INSTITUT: A patent application covering natural or synthetic chalcones in a variety of therapeutic areas. U.S. Patent WO9900114 1999.
36. Rojas, J. et al. Therapeutic administration of 3,4,5-trimethoxy-4β-fluorochalcone, a selective inhibitor of iNOS expression, attenuates the development of adjuvant-induced arthritis in rats. Naunyn-Schmiedebergs Arch. Pharmacol., 2003, 368, 225-233.
37. Zhao, F. et al. Inhibitors of nitric oxide production from hops (Humulus lupulus L). Biol. Pharm. Bull., 2003, 26, 61-65.
38. Cheng, Z.J. et al. Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. Biochem. Pharmacol., 2001, 61, 939-946.
39. Tanaka, S. et al. Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. Planta. Med., 2001, 67, 108-113.
40. Barford, L. et al. Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int. Immunopharmacol., 2002, 2, 545-555.
41. Herencia, F. et al. Nitric oxide-scavenging properties of some chalcone derivatives. Nitric Oxide., 2002, 6, 242-246.
42. Tanaka, S. et al. Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. Planta. Med., 2001, 67, 108-113.
43. Madan, B. et al. 2'-hydroxychalcone inhibits nuclear factor-κB and blocks tumor necrosis factor-alpha-and lipopolysaccharideinduced adhesion of neutrophils to human umbilical vein endothelial cells. Mol. Pharmacol., 2000, 58, 526-341.
44. Gonzalez, R. et al. Effects of Flavonoids and other Polyphenols on Inflammation. Crit. Rev. Food. Sci. Nut., 2011, 51, 331-362.
45. Sawle, P. et al. StructureαActivity Relationships of Methoxychalcones as Inducers of Heme Oxygenase-1. Chem. Res. Toxicol., 2008, 21 (7), 1484-1494.
46. Yang, H.-M. et al. Structural requirement of chalcones for the inhibitory activity of interleukin-5. Bioorg. Med. Chem., 2007, 15 (1), 104-111.
47. Jin, F. et al. Structural requirements of 2β,4β,6β-tris(methoxymethoxy) chalcone derivatives for anti-inflammatory activity: The importance of a 2β-hydroxy moiety. Arch. Pharmacal Res., 2007, 30 (11), 1359-1367.
48. Chiaradia, L. D. et al. Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: Quantitative structure-activity relationships. Bioorg. Med. Chem., 2008, 16 (2), 658-667.
49. Zarghi, A. et al, Synthesis and biological evaluation of 1,3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors. Bioorg. Med. Chem., 2006, 14 (20), 7044-7050.